Lineage Cell Therapeutics, Inc.

DB:BT3 Stock Report

Market Cap: €106.5m

Lineage Cell Therapeutics Management

Management criteria checks 2/4

Lineage Cell Therapeutics' CEO is Brian Culley, appointed in Sep 2018, has a tenure of 6.25 years. total yearly compensation is $2.91M, comprised of 22% salary and 78% bonuses, including company stock and options. directly owns 0.088% of the company’s shares, worth €94.12K. The average tenure of the management team and the board of directors is 3.9 years and 8.1 years respectively.

Key information

Brian Culley

Chief executive officer

US$2.9m

Total compensation

CEO salary percentage22.0%
CEO tenure6.3yrs
CEO ownership0.09%
Management average tenure3.9yrs
Board average tenure8.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Brian Culley's remuneration changed compared to Lineage Cell Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$20m

Jun 30 2024n/an/a

-US$24m

Mar 31 2024n/an/a

-US$24m

Dec 31 2023US$3mUS$640k

-US$21m

Sep 30 2023n/an/a

-US$23m

Jun 30 2023n/an/a

-US$22m

Mar 31 2023n/an/a

-US$24m

Dec 31 2022US$2mUS$609k

-US$26m

Sep 30 2022n/an/a

-US$49m

Jun 30 2022n/an/a

-US$51m

Mar 31 2022n/an/a

-US$49m

Dec 31 2021US$3mUS$580k

-US$43m

Sep 30 2021n/an/a

-US$12m

Jun 30 2021n/an/a

-US$12m

Mar 31 2021n/an/a

-US$14m

Dec 31 2020US$1mUS$552k

-US$21m

Sep 30 2020n/an/a

-US$27m

Jun 30 2020n/an/a

-US$36m

Mar 31 2020n/an/a

-US$59m

Dec 31 2019US$773kUS$536k

-US$12m

Sep 30 2019n/an/a

-US$52m

Jun 30 2019n/an/a

US$31m

Mar 31 2019n/an/a

US$57m

Dec 31 2018US$3mUS$155k

-US$46m

Compensation vs Market: Brian's total compensation ($USD2.91M) is above average for companies of similar size in the German market ($USD466.27K).

Compensation vs Earnings: Brian's compensation has increased whilst the company is unprofitable.

CEO

Brian Culley (53 yo)

6.3yrs

Tenure

US$2,905,130

Compensation

Mr. Brian M. Culley, M.A., M.B.A., served as Interim Chief Financial Officer, Principal Financial Officer at Lineage Cell Therapeutics, Inc. since July 8, 2022 until November 14, 2022. He served as Interim...

Leadership Team

NamePositionTenureCompensationOwnership
Brian Culley
CEO, President & Director6.3yrsUS$2.91m0.088%
€ 94.1k
Jill Howe
CFO & Principal Financial and Accounting Officer2.1yrsUS$738.86k0.012%
€ 12.3k
George Samuel
General Counsel & Company Secretary3.3yrsUS$1.21m0.010%
€ 10.7k
Ioana Hone
Director of Investor Relationsno datano datano data
Charlotte Hubbert
Vice President of Corporate Developmentless than a yearno datano data
Brandi Roberts
Consultant3.9yrsUS$668.25kno data
William Annett
President & CEO of OncoCyte Corporationno dataUS$654.85kno data
Rami Skaliter
Chief Executive Officer of Cell Cure Neurosciencesno datano datano data
Alexandra Hernandez
Senior Director of Finance & Controller5.3yrsno datano data
Harold Waitz
Vice President of Regulatory Affairs & Quality Control29.9yrsUS$90.00kno data

3.9yrs

Average Tenure

53yo

Average Age

Experienced Management: BT3's management team is considered experienced (3.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Brian Culley
CEO, President & Director6.3yrsUS$2.91m0.088%
€ 94.1k
Don Bailey
Independent Director5.8yrsUS$130.50k0.072%
€ 76.7k
Angus Russell
Independent Director10yrsUS$138.00k0.040%
€ 42.3k
Anula Jayasuriya
Independent Director3.6yrsUS$128.00k0.0045%
€ 4.8k
Neal Bradsher
Independent Director15.4yrsUS$141.13k0.040%
€ 42.3k
Deborah Andrews
Independent Director10.7yrsUS$148.00k0.0071%
€ 7.5k
Michael Mulroy
Independent Chairman10.2yrsUS$151.13k0.14%
€ 144.2k
Dipti Amin
Independent Director3.7yrsUS$128.00k0.016%
€ 16.9k

8.1yrs

Average Tenure

63.5yo

Average Age

Experienced Board: BT3's board of directors are considered experienced (8.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 17:36
End of Day Share Price 2024/12/05 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lineage Cell Therapeutics, Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Mayank MamtaniB. Riley Securities, Inc.
Gum-Ming LoweCraig-Hallum Capital Group LLC